Hooper Holmes — Q3 2016 Earnings Presentation
7 slides from Hooper Holmes's earnings presentation, Nov 10, 2016
Slide 1: Q3 2016 Earnings Presentation
Q3 2016 Earnings Presentation November, 2016 Presented By: Henry Dubois, Chief Executive Officer Steven Balthazor, Chief Financial Officer (NYSE Mkt: HH) 1
Slide 2: Safe Harbor Statement
2 Safe Harbor Statement 2 This presentation may contain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may generally be identified by the use of words such as "anticipate," "believe," "expect," "intends," "plan," and "will" or, in each case,
Slide 3: Q3 2016 Highlights
3 Q3 2016 HIGHLIGHTS $9.75mm Health & Wellness revenue. YTD Revenue increased 9% compared to 2015 ̶ Adjusted EBITDA near break-even Higher percentage of Q3 revenues from top Channel Partner and Clinical customers Longer lead time from agreement in principle to contracting for new large custome
Slide 4: Improved Q3 2016 Operating Performance
4 Improved Q3 2016 Operating Performance Adjusted EBITDA ($000’s) 80% Improvement Q3 2015 - 2016 Q3 2015 Q3 2016 Net Loss ($2,118) ($2,052) Interest expense $208 $243 Other Debt related costs in Int exp $180 $635 Income taxes $5 $5 Depreciation & amortization $672 $682 Share-based compensation $167
Slide 5: Growth in core business
5 5 Growth in core business Key Takeaways Core Customer Growth in Q3 2016 R ev en u e C la ss if ic atio n b y sal e s segme n ts Core business solid and growing Growth in Channel Partners revenue reflects strength of our screening services Direct sales channel reflects customers who contract
Slide 6: Building Competitive Advantage
Building Competitive Advantage 6 New Screening services exceed expectations Upgraded Wellness Platform Integrated flu shots and cotinine fingerstick tests with wellness screenings Updated online scheduler Enhanced Wellness Support NowSM onsite health coaching New capabilities to help members
Slide 7: 2017 Outlook
7 2017 Outlook Levers for Growth Improved Operating Performance Compared to Q3 2015: Building Long-Term Growth Creating Value for Shareholders • Gross margin improved 16% • SG&A decreased 4.1% • Adjusted EBITDA improved 80% • Higher percentage of Q3 revenues from top Channel Partner and Clinical cus